Clinical Trial Update: Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating ruxolitinib in patients with low or intermediate-1 risk myelodysplastic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1 | Status: COMPLETED